Catalyst staves off Firdapse competition from Teva for a decade
Catalyst Pharmaceuticals’ controversial $375,000 rare autoimmune disease drug now won’t face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
